Lineage

highly transmissible variant lineage b.1.1.7 OC frequency inferred from genetic data correspond

Abstract

The SARS-CoV-2 lineage B.1.1.7, designated variant of concern (VOC) 202012/01 by Public Health England1, was first identified in the UK in late summer to early autumn 20202. Whole-genome SARS-CoV-2 sequence data collected from community-based diagnostic testing for COVID-19 show an extremely rapid expansion of the B.1.1.7 lineage during autumn 2020, suggesting that it has a selective advantage. Here we show that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S gene target failures (SGTF) in community-based diagnostic PCR testing. Analysis of trends in SGTF and non-SGTF case numbers in local areas across England shows that B.1.1.7 has higher transmissibility than non-VOC lineages, even if it has a different latent period or generation time.

The SGTF data indicate a transient shift in the age composition of reported cases, with cases of B.1.1.7 including a larger share of under 20-year-olds than non-VOC cases. We estimated time-varying reproduction numbers for B.1.1.7 and co-circulating lineages using SGTF and genomic data. The best-supported models did not indicate a substantial difference in VOC transmissibility among different age groups, but all analyses agreed that B.1.1.7 has a substantial transmission advantage over other lineages, with a 50% to 100% higher reproduction number.

Summary

What is already known about this topic?

A more highly transmissible variant of SARS-CoV-2, B.1.1.7, has been detected in start highlight12end highlight U.S. states.

What is added by this report?

Modeling data indicate that B.1.1.7 has the potential to increase the U.S. pandemic trajectory in the coming months. CDC’s system for genomic surveillance and the effort to expand sequencing will increase the availability of timely U.S. genomic surveillance data.

What are the implications for public health practice?

The increased transmissibility of the B.1.1.7 variant warrants universal and increased compliance with mitigation strategies, including distancing and masking. Higher vaccination coverage might need to be achieved to protect the public. Genomic sequence analysis through the National SARS-CoV-2 Strain Surveillance program will enable a targeted approach to identifying variants of concern in the United States.

lineage b.1.1.7
lineage b.1.1.7

Main

The SARS-CoV-2 lineage B.1.1.7 spread rapidly across England between November 2020 and January 2021. This variant possesses a large number of non-synonymous substitutions of immunological importance2. The N501Y replacement on the spike protein has been shown to increase ACE2 binding3,4 and cell infectivity in animal models5, and the P618H replacement on the spike protein adjoins the furin-cleavage site6. B.1.1.7 also possesses a deletion at positions 69 and 70 of the spike protein (Δ69–70) that has been associated with failure of diagnostic tests using the ThermoFisher TaqPath probe, which targets the spike protein7.

Although other variants with Δ69–70 are also circulating in the UK, the absence of detection of the S gene target in an otherwise positive PCR test appears to be a highly specific biomarker for the B.1.1.7 lineage. Data from national community testing in November 2020 showed a rapid increase in SGTF during PCR testing for SARS-CoV-2, coinciding with a rapid increase in the frequency of B.1.1.7 observed in genomic surveillance. The B.1.1.7 lineage was designated VOC 202012/01 by Public Health England (PHE) in December 2020.

We examined whole-genome SARS-CoV-2 sequences from randomly sampled residual materials obtained from community-based COVID-19 testing in England, collected between 1 October 2020 and 16 January 2021. These data included 31,390 B.1.1.7 sequences for which the time and location of sample collection were known.

Over the same period, 52,795 non-VOC genomes were collected. VOC sequences were initially concentrated in London (n = 9,134), the South East (n = 5,609), and the East of England (n = 4,413), but is now widely distributed across England. Overall, we estimate the median posterior additive difference in growth rates between B.1.1.7 and co-circulating variants to be 0.69 per week (95% credible interval (CrI) 0.61–0.76) (Fig. 1a, Extended Data Fig. 1, Supplementary Methods section 2), and this difference was largest in November. However, in tandem with geographic expansion of the VOC and imposition of lockdown measures in 2021, this difference declined gradually to 0.43 per week (95% CrI 0.33–0.52) for the week ending 16 January.

Mixed Lineage Kinase 4 (MLK4) Antibody

abx235216-100ug 100 ug
EUR 661.2

Mixed Lineage Kinase 2 (MLK2) Antibody

abx235214-100ug 100 ug
EUR 661.2

Mixed Lineage Kinase 3 (MLK3) Antibody

abx235215-100ug 100 ug
EUR 577.2

Mixed Lineage Kinase 2 (MLK2) Antibody

20-abx121520
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Mixed Lineage Kinase 2 (MLK2) Antibody

abx033764-400ul 400 ul
EUR 627.6

Mixed Lineage Kinase 2 (MLK2) Antibody

abx033764-80l 80 µl
EUR 343.2

Mixed Lineage Kinase 4 (MLK4) Antibody

abx033812-400ul 400 ul
EUR 627.6

Mixed Lineage Kinase 4 (MLK4) Antibody

abx033812-80l 80 µl
EUR 343.2

Human mixed lineage kinase domain- like ELISA Kit

ELA-E1747h 96 Tests
EUR 988.8

Oligodendrocyte Lineage Transcription Factor 2 Antibody

20-abx114262
  • EUR 878.40
  • EUR 477.60
  • 150 ul
  • 50 ul

Mixed Lineage Kinase-Related Kinase (MLKLAK) Antibody

abx033850-400ul 400 ul
EUR 627.6

Mixed Lineage Kinase-Related Kinase (MLKLAK) Antibody

abx033850-80l 80 µl
EUR 343.2

Human Mixed lineage kinase domain-like protein (MLKL)

1-CSB-EP850851HU
  • EUR 456.00
  • EUR 256.80
  • EUR 1570.80
  • EUR 672.00
  • EUR 1047.60
  • EUR 314.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Mixed lineage kinase domain-like protein(MLKL) expressed in E.coli

Human Mixed lineage kinase domain-like protein (MLKL)

1-CSB-EP850851HUa0
  • EUR 606.00
  • EUR 318.00
  • EUR 2192.40
  • EUR 919.20
  • EUR 1461.60
  • EUR 402.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Mixed lineage kinase domain-like protein(MLKL) expressed in E.coli

Human Mixed lineage kinase domain-like protein (MLKL)

1-CSB-YP850851HU
  • EUR 516.00
  • EUR 280.80
  • EUR 1809.60
  • EUR 770.40
  • EUR 1210.80
  • EUR 349.20
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Mixed lineage kinase domain-like protein(MLKL) expressed in Yeast

Mouse Mixed lineage kinase domain-like protein (Mlkl)

1-CSB-YP861529MO
  • EUR 604.80
  • EUR 318.00
  • EUR 2198.40
  • EUR 915.60
  • EUR 1459.20
  • EUR 400.80
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) expressed in Yeast

Mixed Lineage Kinase Domain Like Protein (MLKL) Antibody

20-abx323829
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Hematopoietic Lineage Cell-Specific Protein (HS1) Antibody

20-abx012993
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Rat mixed lineage kinase domain-like (MLKL)ELISA Kit

YLA1503RA-48T 48T
EUR 465

Rat mixed lineage kinase domain-like (MLKL)ELISA Kit

YLA1503RA-96T 96T
EUR 600

Mixed Lineage Kinase Domain-Like Protein (MLKL) Antibody

abx235217-100ug 100 ug
EUR 661.2

Mixed Lineage Kinase Domain-Like Protein (MLKL) Antibody

20-abx119566
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Mixed Lineage Kinase Domain-Like Protein (MLKL) Antibody

20-abx125368
  • EUR 594.00
  • EUR 844.80
  • EUR 427.20
  • 100 ul
  • 200 ul
  • 50 ul

Mixed Lineage Kinase Domain-Like Protein (MLKL) Antibody

20-abx004271
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Mixed Lineage Kinase Domain-Like Protein (MLKL) Antibody

20-abx301603
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx233786-100ug 100 ug
EUR 661.2

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx117237-100ug 100 ug
EUR 560.4

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx330735-100ul 100 ul
EUR 510

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx027757-400ul 400 ul
EUR 627.6

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx027757-80l 80 µl
EUR 343.2

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

abx037846-100ug 100 ug
EUR 469.2

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

20-abx323266
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Hematopoietic Lineage Cell-Specific Protein (HCLS1) Antibody

20-abx001777
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

human mixed lineage kinase domain-like,MLKL ELISA Kit

201-12-1876 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human mixed lineage kinase domain-like(MLKL)ELISA Kit

GA-E1892HM-48T 48T
EUR 346.8

Human mixed lineage kinase domain-like(MLKL)ELISA Kit

GA-E1892HM-96T 96T
EUR 559.2

Human MLKL(mixed lineage kinase domain-like) ELISA Kit

EH10133 96T
EUR 681.12
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml

Human mixed lineage kinase domain-like(MLKL)ELISA Kit

QY-E03085 96T
EUR 433.2

Dodaj komentarz

Twój adres e-mail nie zostanie opublikowany. Wymagane pola są oznaczone *